Gilead Sciences joins GVN's pharma coalition

By The Science Advisory Board staff writers

June 30, 2021 -- The Global Virus Network (GVN), a coalition of virologists, announced that Gilead Sciences has joined its Healthcare and Pharma Center of Excellence Coalition.

The excellence coalition aims to use the expertise and resources of pharmaceutical companies to lead the charge against viruses threatening public health.

Gilead joins Abbott and Sanofi Pasteur in developing therapies and treatments for viral threats and diseases, including Zika, Ebola, and dengue.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.